{
  "slug": "cleancard",
  "name": "Cleancard",
  "yc_id": 28891,
  "batch": "Summer 2023",
  "website": "https://www.cleancard.bio",
  "web_data": {
    "web_enrichment_version": "1.0.0",
    "enriched_at": "2025-10-17T01:25:01.846297",
    "website": "https://www.cleancard.bio",
    "website_status": {
      "reachable": true,
      "status_code": 200,
      "response_time_ms": 1200.62,
      "final_url": "https://www.cleancard.bio/",
      "redirected": true,
      "checked_at": "2025-10-17T01:25:03.046924"
    },
    "ssl_security": {
      "disabled": true,
      "reason": "certificate_verification_failed"
    },
    "domain_info": {
      "domain": "cleancard.bio",
      "error": "Whois command returned no output"
    },
    "social_links": {
      "twitter": null,
      "linkedin": null,
      "github": null,
      "facebook": null,
      "instagram": null,
      "youtube": null
    },
    "security_headers": {
      "strict_transport_security": true,
      "content_security_policy": false,
      "x_frame_options": false,
      "x_content_type_options": false,
      "x_xss_protection": false,
      "referrer_policy": false,
      "security_score": 16,
      "server": "cloudflare"
    }
  },
  "enrichment_version": "1.0.0",
  "enriched_at": "2025-10-17T10:39:18.605145",
  "phase1_complete": true,
  "phase2_complete": false,
  "phase3_complete": false,
  "phase4_complete": false,
  "phase5_complete": false,
  "ai_insights": {
    "ai_insights_version": "1.0.0",
    "model_used": "google/gemini-2.0-flash-001",
    "enriched_at": "2025-10-17T12:41:21.373448",
    "status": "success",
    "market_analysis": {
      "market_size": "very large",
      "market_stage": "growing",
      "key_trends": [
        "Increased focus on early cancer detection",
        "Growing demand for at-home diagnostics",
        "Advancements in synthetic biology and AI in healthcare"
      ]
    },
    "competitive_positioning": {
      "competitive_moat": "Proprietary synthetic biology and AI platform for urine-based cancer detection.",
      "differentiation": "Fully at-home, rapid (30-minute) cancer detection from urine samples.",
      "competitive_advantages": [
        "Convenience and accessibility for patients",
        "Potential for early and frequent monitoring"
      ],
      "competitive_vulnerabilities": [
        "Regulatory hurdles for at-home diagnostics",
        "Accuracy and reliability compared to traditional methods"
      ]
    },
    "business_model": {
      "revenue_model": "Hardware (test kits) and potentially subscription-based biomarker tracking.",
      "scalability": "high",
      "capital_intensity": "medium"
    },
    "growth_assessment": {
      "growth_stage": "seed",
      "growth_indicators": [
        "Successful pilot studies",
        "Partnerships with healthcare providers"
      ],
      "growth_bottlenecks": [
        "Regulatory approval timelines",
        "Scaling manufacturing and distribution"
      ]
    },
    "risk_analysis": {
      "market_risk": "medium",
      "technology_risk": "medium",
      "execution_risk": "medium",
      "overall_risk_score": 6,
      "key_risks": [
        "Clinical validation and accuracy",
        "Competition from established diagnostic companies",
        "Patient adoption and trust"
      ]
    },
    "investment_thesis": {
      "strengths": [
        "Novel technology with potential for significant impact",
        "Large and growing market",
        "Strong team with expertise in synthetic biology and AI"
      ],
      "concerns": [
        "Regulatory pathway and reimbursement",
        "Demonstrating superior performance compared to existing methods"
      ],
      "exit_potential": "acquisition",
      "comparable_companies": [
        "Exact Sciences",
        "Guardant Health"
      ]
    },
    "recommendations": {
      "next_steps": [
        "Focus on clinical validation and regulatory approval",
        "Develop partnerships with healthcare providers and insurers"
      ],
      "expansion_opportunities": [
        "Expand the platform to detect other diseases",
        "Develop personalized cancer monitoring solutions"
      ]
    },
    "tokens_used": {
      "prompt": 693,
      "completion": 516,
      "total": 1209,
      "estimated_cost": 0.000207
    }
  },
  "phase8_complete": true
}